Nexstim Plc has received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD). Released in the EU and the United States in 2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is currently FDA-approved for the treatment of major depressive disorder (MDD), and CE marked for the treatment of major depression and chronic neuropathic pain.

One of the unique features of the NBS 6 is its modular design that allows for expansions of system capabilities over time.